 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Short-Course Treatment for Latent Tuberculosis Is Associated with More Frequent Liver Injury Than Long-Course Treatment Is
15 October 2002 | Volume 137 Issue 8 | Page I-32
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial." It is in the 15 October 2002 issue of Annals of Internal Medicine (volume 137, pages 640-647). The authors are RM Jasmer, JJ Saukkonen, HM Blumberg, CL Daley, J Bernardo, E Vittinghoff, MD King, LM Kawamura, and PC Hopewell, for the Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators.
What is the problem and what is known about it so far?
Tuberculosis is an infection that usually involves the lungs but can also affect other areas of the body. People can develop tuberculosis when exposed to someone with it, especially if the infected person is coughing. People exposed to tuberculosis do not always become sick. The tuberculosis bacteria can "hide out" in a person's body for many years—a situation called latent tuberculosis. Doctors can tell when patients have latent tuberculosis because they have positive tuberculosis skin tests but normal chest x-rays and no symptoms. Because latent tuberculosis can become active many years after exposure, doctors treat people with latent tuberculosis with antibiotics unless their age or medical history makes them at high risk for the side effects of treatment. The most common serious side effect of tuberculosis treatment is liver damage. Guidelines suggest three main treatment options for latent tuberculosis: 1) isoniazid for 6 to 9 months, 2) rifampin for 4 months, or 3) rifampin and pyrazinamide for 2 months. This last option is attractive because patients have to take drugs for only 2 months. Unfortunately, several reports of liver problems in people taking rifampin plus pyrazinamide have raised concerns about the safety of this treatment.
Why did the researchers do this particular study?
To find out whether liver damage is more common in patients treated with rifampin plus pyrazinamide for 2 months than in patients treated with isoniazid for 6 months.
Who was studied?
589 patients with latent tuberculosis who received treatment in one of three tuberculosis clinics in the United States.
How was the study done?
The researchers prescribed 2 months of rifampin plus pyrazinamide for all patients who presented to the clinics one week, isoniazid for patients who presented the next week, and so on until they had assigned treatment to 589 patients. They followed patients closely, checking blood tests of liver function.
What did the researchers find?
207 patients taking rifampin plus pyrazinamide and 204 patients taking isoniazid returned for follow-up. Of the 207 patients taking rifampin plus pyrazinamide, 54 developed some liver damage compared with 32 of the 204 patients taking isoniazid. Liver damage was severe in 16 patients taking rifampin plus pyrazinamide and in 2 patients taking isoniazid.
What were the limitations of the study?
This study could not identify patient characteristics that increase the risk for liver problems during therapy with rifampin plus pyrazinamide.
What are the implications of the study?
If patients and doctors choose to treat latent tuberculosis with 2 months of rifampin plus pyrazinamide, frequent laboratory tests of liver function should be done to screen for liver damage. If blood tests suggest liver damage, patients should stop taking the drugs.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  D. Menzies, R. Long, A. Trajman, M.-J. Dion, J. Yang, H. Al Jahdali, Z. Memish, K. Khan, M. Gardam, V. Hoeppner, et al. Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection: A Randomized Trial Ann Intern Med, November 18, 2008; 149(10): 689 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Blumberg Needed: New and Better Tools to Combat Latent Tuberculosis Infection Ann Intern Med, November 18, 2008; 149(10): 761 - 763. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, D. B. Strader, et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 935 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Page, F. Sifakis, R. Montes de Oca, W. A. Cronin, M. C. Doherty, L. Federline, S. Bur, T. Walsh, W. Karney, J. Milman, et al. Improved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent Tuberculosis: A Retrospective Study. Arch Intern Med, September 25, 2006; 166(17): 1863 - 1870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schechter, R. Zajdenverg, G. Falco, G. L. Barnes, J. C. Faulhaber, J. S. Coberly, R. D. Moore, and R. E. Chaisson Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts Am. J. Respir. Crit. Care Med., April 15, 2006; 173(8): 922 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 British Thoracic Society Standards of Care Committ BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-{alpha} treatment Thorax, October 1, 2005; 60(10): 800 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Younossian, T. Rochat, J-P. Ketterer, J. Wacker, and J-P. Janssens High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis Eur. Respir. J., September 1, 2005; 26(3): 462 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. F. Fountain, E. Tolley, C. R. Chrisman, and T. H. Self Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection: A 7-Year Evaluation From a Public Health Tuberculosis Clinic Chest, July 1, 2005; 128(1): 116 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Blumberg, M. K. Leonard Jr, and R. M. Jasmer Update on the Treatment of Tuberculosis and Latent Tuberculosis Infection JAMA, June 8, 2005; 293(22): 2776 - 2784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Lobato, R. R. Reves, R. M. Jasmer, J. C. Grabau, N. N. Bock, N. Shang, and for the 2RZ Study Group Adverse Events and Treatment Completion for Latent Tuberculosis in Jail Inmates and Homeless Persons Chest, April 1, 2005; 127(4): 1296 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Menzies, M.-J. Dion, B. Rabinovitch, S. Mannix, P. Brassard, and K. Schwartzman Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 445 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mohan, S. K. Sharma, D. Menzies, and D. Yee Side Effects of Antituberculosis Drugs Am. J. Respir. Crit. Care Med., April 1, 2004; 169(7): 882 - 883. [Full Text] [PDF]
|
|
|
|
|
|
C. C. Leung, W. S. Law, K. C. Chang, C. M. Tam, W. W. Yew, C. K. Chan, and M. Y. Wong Initial Experience on Rifampin and Pyrazinamide vs Isoniazid in the Treatment of Latent Tuberculosis Infection Among Patients With Silicosis in Hong Kong Chest, December 1, 2003; 124(6): 2112 - 2118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Weir and D. N. Fisman Latent tuberculosis: revised treatment guidelines Can. Med. Assoc. J., October 28, 2003; 169(9): 937 - 938. [Full Text]
|
|
|
|
|
|
P. A. LoBue and K. S. Moser Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic Am. J. Respir. Crit. Care Med., August 15, 2003; 168(4): 443 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Chaisson Tuberculosis Chemotherapy: Still a Double-edged Sword Am. J. Respir. Crit. Care Med., June 1, 2003; 167(11): 1461 - 1462. [Full Text] [PDF]
|
|
|
|
|
|
D. Yee, C. Valiquette, M. Pelletier, I. Parisien, I. Rocher, and D. Menzies Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis Am. J. Respir. Crit. Care Med., June 1, 2003; 167(11): 1472 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Jasmer and C. L. Daley Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection: Is It Safe? Am. J. Respir. Crit. Care Med., March 15, 2003; 167(6): 809 - 810. [Full Text] [PDF]
|
|
|
|
|
|
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Khan, P. Muennig, M. Behta, and J. G. Zivin Global Drug-Resistance Patterns and the Management of Latent Tuberculosis Infection in Immigrants to the United States N. Engl. J. Med., December 5, 2002; 347(23): 1850 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Jasmer, P. Nahid, and P. C. Hopewell Latent Tuberculosis Infection N. Engl. J. Med., December 5, 2002; 347(23): 1860 - 1866. [Full Text] [PDF]
|
|
|
|
 |
|
 Shorter Regimens Not Necessarily Better for Latent TB Journal Watch (General), November 8, 2002; 2002(1108): 2 - 2. [Full Text]
|
|
|
|
|
|
L. E. Braitman and P. R. Rosenbaum Rare Outcomes, Common Treatments: Analytic Strategies Using Propensity Scores Ann Intern Med, October 15, 2002; 137(8): 693 - 695. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
